Evaluation on clinical efficacy of amlodipine in treatment of mild to moderate hypertension with intensified blood pressure reduction as target
CSTR:
Author:
Affiliation:

(1. Institue of Hepatology, Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, China;2. Department of Neurosurgery, First Medical Center,Beijing 100039, China;5. Department of Emergency Medicine, Second Medical Center, Chinese PLA General Hospital, Beijing 100039, China;3. Beijing Thadweik Academy of Medicine, Beijing 100039, China;4. Jiangsu Provincial Engineering Research Center for Endothelial Cell Targeted Cardiovascular Drug Creation, Xuzhou 221116, Jiangsu Province, China)

Clc Number:

Fund Project:

This study was supported by the Major Project of National Major New Drug Research and Development (2010ZX09401-307, 2008ZXJ09004-018, 2009ZX09301-002).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective To investigate standard-reaching rate of blood pressure reduction in patients with mild to moderate primary hypertension after treatment of amlodipine besylate. Methods Based on the data from a prospective self-controlled trial, the patients with mild to moderate primary hypertension who met our inclusion criteria were enrolled and then treated with a single drug therapy of amlodipine besylate tablet with 5 mg dose for 8 weeks. The efficacy and safety of amlodipine besylate tablet were evaluated, and the standard-reaching rate of blood pressure reduction was calculated with 140/90 and 130/80 mmHg (1 mmHg=0.133 kPa) as blood pressure targets, respectively, and for the patients of different ages. SPSS statistics SAS 9.3 and Graphpad Prism 9.5.1 were used for statistical analysis. Intergroup comparison was performed using student′s t test, Fisher′s exact probability test or Chi-square test depending on data type. Results For the 120 patients included in this study, the decline in systolic (SBP) and diastolic blood pressure (DBP) was (16.7±12.9) and (12.9±7.5) mmHg, respectively, after treatment, with an effective rate of 72.5% (87/120), and an overall effective rate of 91.7% (110/120). Statistical significance was observed in the decrease in blood pressure before and after treatment of amlodipine besylate tablet (P<0.05), which was consistent with literature reports. With 140/90 and 130/80 mmHg as blood pressure targets, the standard-reaching rate was 51.6% (49/95) and 5.0% (6/119), respectively after 8 weeks of treatment (P<0.05). Subgroup analysis showed that the rate was 4.1% (4/98) and 9.5% (2/21), respectively in the younger and older age groups. The incidence of adverse events and adverse reactions was 15.8% (19/120) and 3.3% (4/120), respectively during the treatment period. Conclusion Amlodipine besylate is safe and effective in treatment of mild to moderate primary hypertension. However, when taking the intensified blood pressure reduction target of 130/80 mmHg as the standard, the achievement rate is only 5%. This suggests that monotherapy with commonly used antihypertensive drugs may face challenges in reaching the intensified blood pressure reduction target in clinical practice.

    Reference
    Related
    Cited by
Get Citation
Related Videos

Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:December 12,2023
  • Revised:
  • Adopted:
  • Online: June 18,2024
  • Published:
Article QR Code